ClinicalTrials.gg
Active, not recruitingNCT05387525AKtiveUpdated Feb 11, 2025

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

A Phase 4 interventional study of Tirbanibulin (Klisyri®) 10 mg/g ointment and Diclofenac Sodium 3% Gel in Keratosis, Actinic, sponsored by Almirall, S.A.. Active, not recruiting at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Almirall, S.A. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
447
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Keratosis, Actinic by Almirall, S.A. — none open to participants now, 1 under way, none of them phase 3. Keratosis, Actinic · Almirall, S.A..

Enrollment
3rd of 12
447 · median 307
Started
2022
with 3 others
Phase 4
2 of 14
none open now
Registered
11th of 14
by date

Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 4, and was the 11th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

None of the 14 studies in Keratosis, Actinic by Almirall, S.A. is open now. The open studies under Keratosis, Actinic, anywhere →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Keratosis, Actinic by Almirall, S.A. as a file.
02

Study summary

The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.

03

Conditions studied

  • Keratosis, Actinic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A treatment field (TF) on the face or scalp (excluding lips, eyelids, ears, and inside the nostrils), that: a) is a contiguous area measuring 25 cm\^2, b) contains 2 to 8 clinically typical, visible, and discrete actinic keratosis (AK) lesions, and c) has an overall clinical picture that is consistent with Olsen grade 1
  • If a women of (WOCBP), that is, fertile, defined as a female in the life period from menarche and until becoming (no menses for 12 months without an alternative medical cause) or permanently sterile (with hysterectomy, bilateral salpingectomy or bilateral oophorectomy at least 3 months prior to Screening), she must: a) Have a negative urine pregnancy test using a highly sensitive method at screening and on Day 1 prior to treatment administration. b) Be using effective methods of . c) Agree to have pregnancy tests while in the study and at the end of the study
  • Participants should be willing to avoid sunlight or ultraviolet (UV) light exposure, including the use of tanning beds, to the face or scalp during the study
  • Participants should have the ability to understand the purpose and risks of the study, willingness and ability to comply with the protocol, and provide written in accordance with institutional and regulatory guidelines

Exclusion criteria

Exclusion Criteria:

  • The location of the TF is: a) on any location other than the face or scalp. b) within 5 centimeters (cm) of an incompletely healed wound. c) Within 10 cm of a suspected basal cell carcinoma (BCC) or other neoplasm. d) on the lips, eyelids, ears, or inside the nostrils, periorbital, perioral, or the skin surrounding the nostrils
  • Presence in the TF of: a) clinically atypical and/or rapidly changing AK lesions b) hyperkeratotic or hypertrophic lesions, recalcitrant disease (had cryosurgery on 2 previous occasions), and/or cutaneous horn. c) confluent AK lesions (that is, non-discrete lesions, as per inclusion criterion 2). d) Persisting AK lesions at the screening visit following topical treatment with diclofenac sodium 3 percent (%) gel
  • History of any malignant skin tumour in the TF or history of skin tumour in any region of the body which has metastasized or in which within the study period is likely
  • History of any malignant tumour with systemic antitumor treatment (including radiotherapy) within 12 weeks prior to the Screening Visit or systemic antitumor treatment is expected while on the study
  • participants, including participants with a history of chronic systemic lymphoma or chronic myeloid leukaemia, or organ transplant recipients
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
447 participants (actual)

Study arms

  • Experimental
    Tirbanibulin 10 milligram per gram (mg/g) ointment

    Participants will apply tirbanibulin ointment 10 mg/g once daily to the treatment field (TF) for 5 consecutive days beginning Day 1. At subsequent visits, participants will have the option of an additional 5-day course(s) (with at least 16 weeks between starting date of treatment courses) at the discretion of the investigator if actinic keratosis (AK) lesions are present in the TF and physical treatment is not appropriate.

    Drug: Tirbanibulin (Klisyri®) 10 mg/g ointment

  • Active comparator
    Diclofenac Sodium 3% Gel

    Participants will apply diclofenac sodium 3% gel twice daily to the TF for 60 to 90 days beginning Day 1, with the option of further courses every 6 months (with at least 6 months between starting date of treatment courses) if lesions are found to be present in the TF at follow up visits and physical treatment is not appropriate.

    Drug: Diclofenac Sodium 3% Gel

Interventions

  • DrugTirbanibulin (Klisyri®) 10 mg/g ointment

    Drug page: Tirbanibulin

    Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).

    Also known as: Klisyri®

  • Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF)

    Percentage of participants with histologically confirmed invasive SCC in the TF will be reported as assessed by dermoscopy.

    Time frame: Up to 3 years

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An AE does not necessarily have a causal relationship with the medicinal product.

    Time frame: Up to 3 years

  2. Number of Participants With Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose, resulted in death, was life-threatening (i.e, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

    Time frame: Up to 3 years

  3. Percentage of Participants With any Other Skin Cancer (Other Than SCC) in the TF

    Percentage of participants with any other skin cancer (other than SCC) in the TF will be reported.

    Time frame: Up to 3 years

  4. Time to Occurrence of Invasive SCC From Baseline in the TF

    Time to occurrence of invasive SCC from baseline in the TF will be reported.

    Time frame: Up to 3 years

  5. Percentage of Participants Requiring Rescue Treatment After 1 Treatment Course

    Percentage of participants requiring rescue treatment after 1 treatment course will be reported.

    Time frame: Up to 3 years

  6. Percentage of Participants Requiring Rescue Treatment at Any Time During the Study

    Percentage of participants requiring rescue treatment at any time during the study will be reported.

    Time frame: Up to 3 years

  7. Percentage of Participants With no Lesions After Treatment of the First Recurrence With Tirbanibulin During the First 52 Weeks

    Percentage of participants with no lesions after treatment of the first recurrence with tirbanibulin during the first 52 weeks will be reported.

    Time frame: Up to Week 52

  8. Number of Participants With Vital Signs Abnormalities

    Number of participants with vital signs (including measurement of heart rate, respiratory rate, systolic and diastolic blood pressure and tympanic temperature) will be reported.

    Time frame: Up to 3 years

  9. Number of Participants With Physical Examination Abnormalities

    Number of participants with physical examination abnormalities (height, weight and an assessment of head, eyes, ears, nose and throat, integumentary/dermatological, gastrointestinal, cardiovascular, respiratory, musculoskeletal, and neurological systems) will be reported.

    Time frame: Up to 3 years

07

Study locations

49 sites
  • Almirall Investigation Site 102
    Lille, France
  • Almirall Investigation Site 103
    Marseille, France
  • Almirall Investigation Site 104
    Nice, France
  • Almirall Investigational Site 106
    Paris, France
  • Almirall Investigational Site 105
    Rouen, France
  • Almirall Investigational Site 101
    Saint-Priest-en-Jarez, France
  • Almirall Investigational Site 205
    Augsburg, Germany
  • Almirall Investigational Site 211
    Bad Bentheim, Germany
  • Almirall Investigation Site 201
    Bochum, Germany
  • Almirall Investigational Site 214
    Bochum, Germany
  • Almirall Investigational Site 212
    Bonn, Germany
  • Almirall Investigational Site 208
    Detmold, Germany
  • Almirall Investigational Site 210
    Dresden, Germany
  • Almirall Investigational Site 204
    Erlangen, Germany
  • Almirall Investigational Site 206
    Hamburg, Germany
  • Almirall Investigational Site 213
    Hamburg, Germany
  • Almirall Investigational Site 207
    Marburg, Germany
  • Almirall Investigational Site 209
    Merzig, Germany
  • Almirall Investigation Site 202
    Recklinghausen, Germany
  • Almirall Investigational Site 309
    Arezzo, Italy
  • Almirall Investigational Site 302
    Brescia, Italy
  • Almirall Investigational Site 304
    Genova, Italy
  • Almirall Investigational Site 308
    Modena, Italy
  • Almirall Investigational Site 301
    Napoli, Italy
  • Almirall Investigational Site 303
    Reggio Emilia, Italy
  • Almirall Investigational Site 305
    Roma, Italy
  • Almirall Investigational Site 306
    Roma, Italy
  • Almirall Investigational Site 307
    Roma, Italy
  • Almirall Investigational Site 310
    Rozzano, Italy
  • Almirall Investigational Site 403
    Lublin, Poland
  • Almirall Investigational Site 406
    Rzeszów, Poland
  • Almirall Investigational Site 407
    Warsaw, Poland
  • Almirall Investigational Site 401
    Wrocław, Poland
  • Almirall Investigational Site 402
    Wrocław, Poland
  • Almirall Investigational Site 502
    Barcelona, Spain
  • Almirall Investigational Site 508
    Barcelona, Spain
  • Almirall Investigational Site 510
    Barcelona, Spain
  • Almirall Investigational Site 507
    Granada, Spain
  • Almirall Investigational Site 509
    Granada, Spain
  • Almirall Investigational Site 503
    Madrid, Spain
  • Almirall Investigational Site 504
    Salamanca, Spain
  • Almirall Investigational Site 505
    Sevilla, Spain
  • Almirall Investigational Site 506
    Valence, Spain
  • Almirall Investigational Site 501
    Zaragoza, Spain
  • Almirall Investigational Site 703
    London, United Kingdom
  • Almirall Investigational Site 709
    London, United Kingdom
  • Almirall Investigational Site 708
    Oxford, United Kingdom
  • Almirall Investigational Site 704
    Poole, United Kingdom
  • Almirall Investigational Site 706
    Weston-super-Mare, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jul 2027, 57 months after the start.

Of 19 phase 4 interventional studies under Keratosis, Actinic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 24, 2022
StartActual
Oct 24, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05387525
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Oct 24, 2022
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion